Ronald Cooper
Presidente presso C4 THERAPEUTICS, INC.
Patrimonio netto: 30 210 $ in data 31/05/2024
Profilo
Mr. Ronald H.
Cooper is a Chairman at C4 Therapeutics, Inc., an Independent Director at Generation Bio Co. and a President, Chief Executive Officer & Director at Albireo AB.
He is on the Board of Directors at Generation Bio Co., Albireo Ltd.
and Albireo AB.
Mr. Cooper was previously employed as an Independent Director by Genocea Biosciences, Inc., a Chief Executive Officer by Albireo Pharma, Inc., and a President-Europe by Bristol Myers Squibb Co. He received his undergraduate degree from St. Francis Xavier University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
GENERATION BIO CO.
0.01% | 06/06/2024 | 9 500 ( 0.01% ) | 30 210 $ | 31/05/2024 |
Posizioni attive di Ronald Cooper
| Società | Posizione | Inizio |
|---|---|---|
| GENERATION BIO CO. | Direttore/Membro del Consiglio | 01/03/2021 |
| C4 THERAPEUTICS, INC. | Presidente | 07/06/2024 |
Albireo Ltd.
 Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | Direttore/Membro del Consiglio | 01/09/2015 |
Albireo AB
 Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | Amministratore Delegato | - |
Precedenti posizioni note di Ronald Cooper
| Società | Posizione | Fine |
|---|---|---|
| GENOCEA BIOSCIENCES, INC. | Direttore/Membro del Consiglio | 12/04/2021 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/11/2015 |
| ALBIREO PHARMA, INC. | Amministratore Delegato | - |
Formazione di Ronald Cooper
| St. Francis Xavier University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| GENERATION BIO CO. | Health Technology |
| C4 THERAPEUTICS, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Albireo Ltd.
Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | Health Technology |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | Health Technology |
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
- Borsa valori
- Insiders
- Ronald Cooper
